Treatment of tamoxifen-refractory breast cancer--approach by animal models.
Iino
Y
Y
Department of Emergency and Critical Care Medicine, Gunma University Faculty of Medicine, 3-39-15 Showa-machi, Maebashi, Gunma 371-8511, Japan.
D015127:9,10-Dimethyl-1,2-benzanthracene; D020533:Angiogenesis Inhibitors / Q000494:pharmacology; D000818:Animals; D018931:Antineoplastic Agents, Hormonal / Q000494:pharmacology*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage / Q000494:pharmacology*; D003510:Cyclohexanes; D004195:Disease Models, Animal; D005260:Female; D008325:Mammary Neoplasms, Experimental / Q000139:chemically induced / Q000188:drug therapy*; D051379:Mice; D008819:Mice, Nude; D000077609:O-(Chloroacetylcarbamoyl)fumagillol; D010844:Picibanil / Q000494:pharmacology; D011379:Prognosis; D051381:Rats; D011960:Receptors, Estrogen / Q000187:drug effects; D018570:Risk Assessment; D012717:Sesquiterpenes / Q000494:pharmacology; D013629:Tamoxifen / Q000494:pharmacology*; D005641:Tegafur / Q000008:administration & dosage; D017211:Treatment Failure; D014498:Uracil / Q000008:administration & dosage
D020533:Angiogenesis Inhibitors; D018931:Antineoplastic Agents, Hormonal; D003510:Cyclohexanes; D011960:Receptors, Estrogen; D012717:Sesquiterpenes; D013629:Tamoxifen; D005641:Tegafur; D010844:Picibanil; D014498:Uracil; D015127:9,10-Dimethyl-1,2-benzanthracene; D000077609:O-(Chloroacetylcarbamoyl)fumagillol